Literature DB >> 2610754

Immunophenotypic profile of CNS lymphoma: a review of eighteen cases.

R Bashir1, A Freedman, N Harris, K Bain, L Nadler, F Hochberg.   

Abstract

The cell surface antigenic phenotype of 18 cases of central nervous system (CNS) large-cell lymphoma (14 primary, four secondary) was examined by an immunoperoxidase technique using antibodies that identify B cell restricted and associated antigens. All cases were shown to be of B cell origin by virtue of the expression of monotypic immunoglobulin (Ig) (16 IgM, two IgG) and the pan B cell antigen B1 (CD20). A panel of monoclonal antibodies directed against B cell restricted and associated activation antigens including B5, Blast-1, Blast-2 (CD23), BB1, interleukin 2 receptor (IL2R, CD25), T9 (transferrin receptor) and TNK-TAR (4F2) was used on 12 of the cases. The majority expressed T9 and TNK-TAR. Blast-1 was expressed by less than half the cases and Blast-2 and B5 by one of 12 cases each. This is in contrast to 10 non-CNS diffuse large cell lymphomas where B5 and Blast-1 were present on all cases. This study confirms previous observations that primary CNS large cell lymphomas are of B cell derivation. Moreover, the differences in expression of B cell activation antigens on CNS large cell lymphomas as compared to non-CNS lymphomas raise the possibility that a subset of neoplastic B cells may have unique tropism for the CNS.

Entities:  

Mesh:

Year:  1989        PMID: 2610754     DOI: 10.1007/bf00172918

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  41 in total

1.  B5, a new B cell-restricted activation antigen.

Authors:  A S Freedman; A W Boyd; K C Anderson; D C Fisher; S F Schlossman; L M Nadler
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

2.  Risk of cancer in renal-transplant recipients.

Authors:  R Hoover; J F Fraumeni
Journal:  Lancet       Date:  1973-07-14       Impact factor: 79.321

3.  Characterization of a human B lymphocyte-specific antigen.

Authors:  P Stashenko; L M Nadler; R Hardy; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

4.  Clinical relevance of immunologic phenotype in diffuse large cell lymphoma.

Authors:  S J Horning; R S Doggett; R A Warnke; R F Dorfman; R S Cox; R Levy
Journal:  Blood       Date:  1984-05       Impact factor: 22.113

5.  Cell surface markers for diagnosis of central nervous system involvement in lymphoproliferative diseases.

Authors:  J Ernerudh; T Olsson; G Berlin; B Gustafsson; H Karlsson
Journal:  Ann Neurol       Date:  1986-11       Impact factor: 10.422

6.  The role of the transferrin receptor in human B lymphocyte activation.

Authors:  L M Neckers; G Yenokida; S P James
Journal:  J Immunol       Date:  1984-11       Impact factor: 5.422

7.  Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford.

Authors:  T L Helle; R H Britt; T V Colby
Journal:  J Neurosurg       Date:  1984-01       Impact factor: 5.115

8.  Histochemical and immunohistochemical study of diffuse large-cell lymphomas.

Authors:  C Y Li; G Harrison
Journal:  Am J Clin Pathol       Date:  1978-11       Impact factor: 2.493

9.  Primary lymphoma of the central nervous system.

Authors:  L Letendre; P M Banks; D F Reese; R H Miller; P W Scanlon; J M Kiely
Journal:  Cancer       Date:  1982-03-01       Impact factor: 6.860

10.  B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes.

Authors:  L M Nadler; K C Anderson; G Marti; M Bates; E Park; J F Daley; S F Schlossman
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

View more
  7 in total

1.  Epstein-Barr virus and brain lymphomas.

Authors:  R M Bashir; F H Hochberg; M X Wei
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

2.  Detection of Eber-1 RNA in primary brain lymphomas in immunocompetent and immunocompromised patients.

Authors:  R Bashir; B McManus; C Cunningham; D Weisenburger; F Hochberg
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

3.  Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.

Authors:  Alfredo D Voloschin; Rebecca Betensky; Patrick Y Wen; Fred Hochberg; Tracy Batchelor
Journal:  J Neurooncol       Date:  2007-09-21       Impact factor: 4.130

Review 4.  Primary central nervous system lymphomas--an update.

Authors:  K A Jellinger; W Paulus
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Expression of LFA-1/ICAM-1 in CNS lymphomas: possible mechanism for lymphoma homing into the brain.

Authors:  R Bashir; H Coakham; F Hochberg
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

Review 6.  The therapy of primary brain lymphoma.

Authors:  F H Hochberg; J S Loeffler; M Prados
Journal:  J Neurooncol       Date:  1991-06       Impact factor: 4.130

Review 7.  Primary central nervous system lymphoma with systemic metastasis: case report and review.

Authors:  M T Brown; R E McClendon; J P Gockerman
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.